Ionis Pharmaceuticals Inc (IONS)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$42.93-2.23%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Ionis Pharmaceuticals Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	233.96M
EPS	—	-1.048
Annual ending 2026-12-31
Revenue	—	924.97M
EPS	—	-3.576
Annual ending 2027-12-31
Revenue	—	1.34B
EPS	—	-2.085

Management figures unavailable.

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
DAWNZERA product sales reach $110-120 million	DAWNZERA sales aim for $110-120 million in 2026.	Intact	DAWNZERA sales fall below $100 million in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 2 of last 2 quarters. DAWNZERA sales increased from $16 million in 2026-Q1 to $26 million in 2026-Q2. Full year 2026 sales guidance is $110-120 million. Sales growth and guidance confirm management is delivering on this priority. Delivery assessment Oct 24, 2026
Improvement in EPS trajectory toward break-even	A supporting condition in Ionis Pharmaceuticals Inc's published investment case. The stated target is EPS loss narrows toward -$0.6 per share in 2027.	Broken	EPS loss worsens beyond -$1.0 per share in FY27	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Total revenue grows by about 20% year over year	Ionis is growing revenue about 20% a year.	Improving	YoY revenue growth falls below 15% in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Revenue grew from $246 million in 2026-Q1 to $268 million in 2026-Q2. The company raised full-year 2026 revenue guidance from $800-825 million to $875-900 million. Management's statements and financials show delivering progress on revenue growth. Delivery assessment Oct 24, 2026
TRYNGOLZA peak net sales exceed $2 billion	TRYNGOLZA has FDA approval and targets over $2 billion in peak sales.	Intact	TRYNGOLZA peak sales potential drops below $1.5 billion	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-2.08

$-1.84 → $-2.08 · observed estimates

FY2027 revenue$1.34B

$1.39B → $1.34B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-1.84	$1,388,206,009	9 / 17
2026-07-25	$-1.84	$1,388,206,009	9 / 17
2026-07-26	$-1.07	$1,393,462,710	7 / 21
2026-07-27	$-1.07	$1,392,719,860	7 / 21
2026-07-28	$-1.78	$1,387,423,649	9 / 17
2026-07-29	$-1.78	$1,387,423,649	9 / 17
2026-07-30	$-1.07	$1,392,719,860	7 / 21
2026-07-31	$-1.52	$1,403,804,250	5 / 21
2026-08-01	$-1.79	$1,400,608,511	7 / 17
2026-08-02	$-1.44	$1,406,328,060	7 / 21
2026-08-03	$-1.44	$1,406,328,060	7 / 21
2026-08-04	$-1.44	$1,406,328,060	7 / 21
2026-08-05	$-1.16	$1,401,507,820	9 / 22
2026-08-06	$-1.16	$1,401,507,820	9 / 22
2026-08-07	$-1.89	$1,378,149,446	10 / 17
2026-08-08	$-1.89	$1,378,149,446	10 / 17
2026-08-09	$-1.16	$1,401,507,880	9 / 22
2026-08-10	$-1.89	$1,378,149,446	10 / 17
2026-08-12	$-1.89	$1,378,149,446	10 / 17
2026-08-13	$-1.89	$1,378,149,446	10 / 17
2026-08-14	$-1.89	$1,378,149,446	10 / 17
2026-08-15	$-1.89	$1,378,149,446	10 / 17
2026-08-16	$-1.89	$1,378,149,446	10 / 17
2026-08-17	$-1.89	$1,378,149,446	10 / 17
2026-08-18	$-1.89	$1,378,149,446	10 / 17
2026-08-19	$-1.89	$1,378,149,446	10 / 17
2026-08-20	$-1.93	$1,379,995,467	10 / 18
2026-08-21	$-1.93	$1,379,995,467	10 / 18
2026-08-22	$-1.93	$1,379,995,467	10 / 18
2026-08-23	$-1.93	$1,379,995,467	10 / 18
2026-08-24	$-1.93	$1,379,995,467	10 / 18
2026-08-25	$-1.93	$1,379,995,467	10 / 18
2026-08-26	$-1.93	$1,379,990,921	10 / 18
2026-08-27	$-1.93	$1,379,990,921	10 / 18
2026-08-28	$-1.93	$1,379,990,921	10 / 18
2026-08-29	$-1.93	$1,379,828,508	10 / 18
2026-08-30	$-1.93	$1,379,828,508	10 / 18
2026-08-31	$-1.93	$1,379,828,508	10 / 18
2026-09-01	$-1.93	$1,379,834,912	10 / 18
2026-09-02	$-1.93	$1,379,829,653	11 / 18
2026-09-03	$-1.93	$1,379,829,653	11 / 18
2026-09-04	$-1.93	$1,379,829,653	11 / 18
2026-09-05	$-1.93	$1,379,301,915	11 / 18
2026-09-06	$-1.93	$1,380,600,419	11 / 18
2026-09-07	$-1.93	$1,380,260,495	11 / 18
2026-09-08	$-1.93	$1,345,138,268	11 / 18
2026-09-09	$-1.97	$1,325,555,337	11 / 18
2026-09-10	$-1.97	$1,325,555,337	11 / 18
2026-09-11	$-1.97	$1,325,555,337	11 / 18
2026-09-12	$-1.97	$1,325,555,337	11 / 18
2026-09-13	$-1.97	$1,325,555,337	11 / 18
2026-09-14	$-1.97	$1,325,555,337	11 / 18
2026-09-15	$-1.97	$1,325,555,337	11 / 18
2026-09-16	$-1.99	$1,321,031,528	11 / 18
2026-09-17	$-1.99	$1,321,031,528	11 / 18
2026-09-18	$-2.00	$1,321,031,528	11 / 18
2026-09-19	$-2.00	$1,321,031,528	11 / 18
2026-09-20	$-2.00	$1,321,031,528	11 / 18
2026-09-21	$-2.00	$1,321,031,528	11 / 18
2026-09-22	$-2.00	$1,321,031,528	11 / 18
2026-09-23	$-2.00	$1,321,031,528	11 / 18
2026-09-24	$-2.00	$1,313,262,909	11 / 18
2026-09-25	$-2.04	$1,307,967,509	11 / 18
2026-09-26	$-2.04	$1,307,967,509	11 / 18
2026-09-27	$-2.04	$1,307,967,509	11 / 18
2026-09-28	$-2.04	$1,307,967,509	11 / 18
2026-09-29	$-2.04	$1,307,967,509	11 / 18
2026-09-30	$-2.04	$1,307,967,509	11 / 18
2026-10-01	$-2.04	$1,307,968,609	11 / 18
2026-10-02	$-2.04	$1,307,968,609	11 / 18
2026-10-03	$-2.04	$1,307,968,609	11 / 18
2026-10-04	$-2.04	$1,307,968,609	11 / 18
2026-10-05	$-2.04	$1,307,968,609	11 / 18
2026-10-06	$-2.04	$1,307,968,609	11 / 18
2026-10-07	$-2.04	$1,307,968,609	11 / 18
2026-10-08	$-2.04	$1,307,968,609	11 / 18
2026-10-09	$-2.04	$1,343,338,217	11 / 18
2026-10-10	$-2.05	$1,341,377,768	11 / 18
2026-10-11	$-2.05	$1,341,377,768	11 / 18
2026-10-12	$-2.05	$1,341,377,768	11 / 18
2026-10-13	$-2.10	$1,343,373,582	11 / 18
2026-10-14	$-2.10	$1,343,373,582	11 / 18
2026-10-15	$-2.10	$1,343,373,582	11 / 18
2026-10-16	$-2.07	$1,343,464,962	11 / 19
2026-10-17	$-2.07	$1,343,464,962	11 / 19
2026-10-18	$-2.07	$1,343,464,962	11 / 19
2026-10-19	$-2.07	$1,343,464,962	11 / 19
2026-10-20	$-2.07	$1,343,466,179	11 / 19
2026-10-21	$-2.07	$1,343,881,992	11 / 19
2026-10-22	$-2.07	$1,343,880,775	11 / 19
2026-10-23	$-2.08	$1,341,282,446	11 / 19
2026-10-24	$-2.08	$1,341,282,446	11 / 19

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	21	6	0
2026-06-01	21	5	0
2026-07-01	21	4	0
2026-08-01	19	5	0
2026-09-01	19	6	5
2026-10-01	21	5	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 21 Buy / Strong Buy · 5 Hold · 0 Sell / Strong Sell

2 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 2 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

BMO CapitalOct 21 · prior Sep 8

$54.00 → $66.00+22.2%

Raymond JamesOct 20 · prior Sep 8

$84.00 → $79.00-6.0%

UBSOct 15

$88.00New observation · no comparable prior

$0$48.40$96.80

1 raises · 1 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

DAWNZERA product sales reach $110-120 millionDirect metric needs a verified mapping
Improvement in EPS trajectory toward break-evenPublished status: Broken
Total revenue grows by about 20% year over yearDirect metric needs a verified mapping
TRYNGOLZA peak net sales exceed $2 billionDirect metric needs a verified mapping

Next proof point

Nov 4, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.0%Typical daily move · historical

Downside history

-51.0%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Ionis Pharmaceuticals Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a growth-oriented biotech business, not yet a profitable compounder. The long-term thesis remains intact, with recent progress in revenue and launches, but the evidence is mixed on TRYNGOLZA and overall risk is elevated.

What's priced into Ionis Pharmaceuticals Inc

The valuation is tagged as justified, and the model indicates IONS is cheap versus peers, with medium confidence. The expectations gap is negative, suggesting expectations may be demanding despite the peer discount; the evidence does not give enough detail to state exactly what growth the market assumes.

What the fundamentals likely do

Near term, revenue progress is encouraging: second-quarter revenue rose from the first quarter, and management raised its 2026 revenue guidance. DAWNZERA sales are advancing toward guidance, while TRYNGOLZA progress is mixed; the company remains loss-making, and a guidance cut or broader economic weakness could weigh on execution.

What Ionis Pharmaceuticals Inc hinges on

Over the next few quarters, the thesis hinges on delivering the raised revenue outlook and growing DAWNZERA and TRYNGOLZA sales. Guidance cuts would weaken the case, while continued strength from healthcare peers could support the sector backdrop; the jobs trend is another risk signal.